Related Experiment Video
Updated: Aug 7, 2026

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
Published on: January 21, 2018
alpha2-adrenoceptor agonists as nasal decongestants
M R Corboz1, J C Mutter, M A Rivelli
1Pulmonary and Peripheral Neurobiology, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. michel.corboz@spcorp.com
Selective alpha(2)-adrenoceptor agonists effectively reduce nasal congestion by targeting venous sinusoids. These compounds offer a promising alternative to nonselective decongestants, potentially minimizing side effects like hypertension.
Area of Science:
- Pharmacology
- Otorhinolaryngology
Background:
- Nasal congestion in rhinitis stems from engorged nasal mucosa and obstructed airflow.
- Sympathomimetic alpha-adrenoceptor agonists are the only drugs targeting vascular features of nasal obstruction.
- Nonselective agonists cause side effects like hypertension and nervousness.
Purpose of the Study:
- To evaluate the decongestant effects of selective alpha(2)-adrenoceptor agonists.
- To investigate the mechanism of action on nasal mucosa vasculature.
Main Methods:
- Assessed alpha(2)-adrenoceptor agonists (BHT-920, PGE-6201204) in isolated nasal mucosa contractile bioassays (dog, pig, monkey).
- Utilized a real-time tissue contractility assay with pig nasal explants for BHT-920.
- Evaluated PGE-6201204's in vivo decongestant activity in a cat model.
Main Results:
- Alpha(2)-adrenoceptor agonists contracted nasal mucosa across species.
- Demonstrated preferential vasoconstriction of capacitance vessels (veins, sinusoids).
- Observed significant nasal decongestion effects.
Conclusions:
- Selective alpha(2)-adrenoceptor agonists constrict nasal venous sinusoids and veins.
- These agonists effectively decongest nasal passages.
- Targeting alpha(2)-adrenoceptors offers a potential strategy for nasal congestion treatment with reduced side effects compared to nonselective agents.
Related Concept Videos
Upper Respiratory Drugs: Decongestants
Most decongestants are readily available over-the-counter in various...
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Adrenergic Agonists: Therapeutic Classification
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...

